Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Cardiovascular Systems Inc is a medical devices business based in the US. Cardiovascular Systems shares (CSII) are listed on the NASDAQ and all prices are listed in US Dollars. Cardiovascular Systems employs 780 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$34.15|
|52-week range||$31.20 - $48.28|
|50-day moving average||$33.96|
|200-day moving average||$37.63|
|Wall St. target price||$45.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.35|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||0.56%|
|1 month (2021-09-28)||2.65%|
|3 months (2021-07-28)||-16.59%|
|6 months (2021-04-28)||-16.65%|
|1 year (2020-10-28)||-4.82%|
|2 years (2019-10-28)||-29.73%|
|3 years (2018-10-26)||0.56%|
|5 years (2016-10-28)||53.48%|
Valuing Cardiovascular Systems stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cardiovascular Systems's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cardiovascular Systems's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 177.27. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cardiovascular Systems's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Cardiovascular Systems's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.6 million.
The EBITDA is a measure of a Cardiovascular Systems's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$259 million|
|Gross profit TTM||$197.8 million|
|Return on assets TTM||-2.16%|
|Return on equity TTM||-4.97%|
|Market capitalisation||$1.4 billion|
TTM: trailing 12 months
There are currently 1.1 million Cardiovascular Systems shares held short by investors – that's known as Cardiovascular Systems's "short interest". This figure is 19.5% down from 1.4 million last month.
There are a few different ways that this level of interest in shorting Cardiovascular Systems shares can be evaluated.
Cardiovascular Systems's "short interest ratio" (SIR) is the quantity of Cardiovascular Systems shares currently shorted divided by the average quantity of Cardiovascular Systems shares traded daily (recently around 191135.72621035). Cardiovascular Systems's SIR currently stands at 5.99. In other words for every 100,000 Cardiovascular Systems shares traded daily on the market, roughly 5990 shares are currently held short.
However Cardiovascular Systems's short interest can also be evaluated against the total number of Cardiovascular Systems shares, or, against the total number of tradable Cardiovascular Systems shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cardiovascular Systems's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Cardiovascular Systems shares in existence, roughly 30 shares are currently held short) or 0.0436% of the tradable shares (for every 100,000 tradable Cardiovascular Systems shares, roughly 44 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cardiovascular Systems.
Find out more about how you can short Cardiovascular Systems stock.
We're not expecting Cardiovascular Systems to pay a dividend over the next 12 months.
Cardiovascular Systems's shares were split on a 1:10 basis on 25 February 2009. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiovascular Systems shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cardiovascular Systems shares which in turn could have impacted Cardiovascular Systems's share price.
Over the last 12 months, Cardiovascular Systems's shares have ranged in value from as little as $31.2 up to $48.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiovascular Systems's is 0.8725. This would suggest that Cardiovascular Systems's shares are less volatile than average (for this exchange).
Cardiovascular Systems, Inc. , a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.